Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-06-05 DOI:10.1080/21645515.2023.2214495

Patrick Dmc Katoto, Jacques L Tamuzi, Amanda S Brand, Diana M Marangu, Liliane N Byamungu, Charles S Wiysonge, Glenda Gray

{"title":"Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.","authors":"Patrick Dmc Katoto, Jacques L Tamuzi, Amanda S Brand, Diana M Marangu, Liliane N Byamungu, Charles S Wiysonge, Glenda Gray","doi":"10.1080/21645515.2023.2214495","DOIUrl":null,"url":null,"abstract":"<p><p>The rapid emergence of COVID-19 variants of concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness of the BNT162b2 vaccination among adolescents against symptomatic and severe COVID-19 diseases using mostly real-world data (15 studies). We searched international databases until May 2022 and used Cochrane's risk of bias tools for critical appraisal. Random effects models were used to examine overall vaccine effectiveness (VE) across studies (general inverse-variance) and the effect of circulating VOCs on VE (log relative ratio and VE). Meta-regression assessed the effect of age and time on VE (restricted-maximum likelihood). BNT162b2 VE against PCR-confirmed SARS-CoV-2 was 82.7% (95%CI: 78.37-87.31%). VE was higher for severe (88%) than non-severe (35%) outcomes and declining over time improved following booster dose in omicron era [73%(95%CI:65-81%)]. Fully vaccinated adolescents are protected from COVID-19 circulating VOCs by BNT162b2 especially for the need of critical care or life support.</p>","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2214495"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/e5/KHVI_19_2214495.PMC10294753.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2214495","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The rapid emergence of COVID-19 variants of concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness of the BNT162b2 vaccination among adolescents against symptomatic and severe COVID-19 diseases using mostly real-world data (15 studies). We searched international databases until May 2022 and used Cochrane's risk of bias tools for critical appraisal. Random effects models were used to examine overall vaccine effectiveness (VE) across studies (general inverse-variance) and the effect of circulating VOCs on VE (log relative ratio and VE). Meta-regression assessed the effect of age and time on VE (restricted-maximum likelihood). BNT162b2 VE against PCR-confirmed SARS-CoV-2 was 82.7% (95%CI: 78.37-87.31%). VE was higher for severe (88%) than non-severe (35%) outcomes and declining over time improved following booster dose in omicron era [73%(95%CI:65-81%)]. Fully vaccinated adolescents are protected from COVID-19 circulating VOCs by BNT162b2 especially for the need of critical care or life support.

Abstract Image

查看原文本刊更多论文

2019冠状病毒病辉瑞- biontech (BNT162b2) mRNA疫苗在12-17岁青少年中的有效性:一项系统综述和荟萃分析

新冠肺炎变异毒株（VOCs）的迅速出现阻碍了疫苗的接种。为了向政策提供信息，我们主要使用真实世界的数据（15项研究）调查了BNT162b2疫苗在青少年中对有症状和严重新冠肺炎疾病的有效性。我们搜索了国际数据库，直到2022年5月，并使用Cochrane的偏见风险工具进行批判性评估。随机效应模型用于检验研究中的总体疫苗有效性（VE）（一般逆方差）和循环挥发性有机物对VE的影响（对数相对比和VE）。荟萃回归评估了年龄和时间对VE（受限最大似然）的影响。BNT162b2对经PCR证实的严重急性呼吸系统综合征冠状病毒2型的VE为82.7%（95%可信区间：78.37-87.31%）。在奥密克戎时代，重症（88%）患者的VE高于非重症（35%）患者，随着时间的推移，VE的下降在加强剂量后有所改善[73%（95%置信区间：65-81%）]。BNT162b2保护完全接种疫苗的青少年免受新冠肺炎循环VOCs的影响，特别是在需要重症监护或生命支持的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.